Advantage Alpha Capital Partners LP lessened its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 20.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 69,182 shares of the biotechnology company's stock after selling 18,209 shares during the quarter. Advantage Alpha Capital Partners LP's holdings in ADMA Biologics were worth $1,186,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in the business. Natixis Advisors LLC acquired a new position in shares of ADMA Biologics in the 3rd quarter valued at about $345,000. Mutual of America Capital Management LLC bought a new position in ADMA Biologics in the third quarter worth about $701,000. Thrivent Financial for Lutherans acquired a new position in ADMA Biologics in the third quarter valued at approximately $3,802,000. Jennison Associates LLC bought a new position in shares of ADMA Biologics during the third quarter valued at approximately $690,000. Finally, Intech Investment Management LLC acquired a new stake in shares of ADMA Biologics during the 3rd quarter worth approximately $1,242,000. Institutional investors own 75.68% of the company's stock.
Wall Street Analysts Forecast Growth
Separately, Cantor Fitzgerald restated an "overweight" rating and set a $25.00 price objective on shares of ADMA Biologics in a research report on Tuesday, March 4th.
Get Our Latest Research Report on ADMA Biologics
ADMA Biologics Stock Performance
ADMA Biologics stock traded down $0.02 during midday trading on Friday, reaching $20.26. 2,360,170 shares of the stock traded hands, compared to its average volume of 3,517,452. ADMA Biologics, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $23.64. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The firm has a market cap of $4.79 billion, a price-to-earnings ratio of 72.36 and a beta of 0.60. The firm has a fifty day moving average price of $17.13 and a two-hundred day moving average price of $18.14.
About ADMA Biologics
(
Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Featured Stories
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
